MarketInOut Stock Screener Log In | Sign Up

Altimmune Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/17/2026 16:00
Altimmune Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization320.1 mln
Float184 mln
Earnings Date03/03/2027

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

23.54
Highly suspicious

1-Year Forecast

16.67
Transformational upside

Relative Strength

11 / 100
Significantly lagging

Debt / Equity

0.08
Debt-free

Pre-Tax Margin

-401,362%
Severely loss-making

Business Description

Altimmune is a medical research company working to bring new treatments to patients suffering from serious liver conditions. Its main drug in development, pemvidutide, targets two key biological pathways at once and is currently being tested in late-stage clinical trials for liver disease linked to metabolic dysfunction as well as alcohol-related conditions. Founded in 1997 and based in Gaithersburg, Maryland, the company is focused on advancing this treatment toward potential approval.

Key Fundamentals

EPS-0.71
ROE-32.36
RPS0.00
ROIC-131
ROA-28.10
Interest Cover-27.65
EBITDA, mln-100
EV / EBITDA-0.91
EV / EBIT-0.91
Revenue, mln0.03
EV / Revenue3,503

Quote Details

Last 1.53
Change -0.03 (-1.92%)
Open 1.55
Volume 4,243,659
Turnover 6,492,798
Average Volume 4,009,096

Financial Ratios

Pre-Tax Profit Margin-401,362
Leverage Ratio1.12
Current Ratio23.91
Price / Book0.72
Price / Tangible Book0.72
Debt / Equity0.08
Price / Sales12,307
PEG Ratio32.62

Financial Strength

Altman Z-Score1.61
Piotroski F-Score 4 / 9
Beneish M-Score23.54
1-Year Target Price16.67
Short Ratio10.98
Short % of Float21.68

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -21.13% 7 / 100   
1 Month -31.39% 12 / 100   
2 Months -47.78% 14 / 100   
6 Months -44.16% 17 / 100   
1 Year -63.31% 14 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog